Articles tagged with Cancer Patients
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
A survey found that spiritual beliefs and distrust of clinical research contribute to Black patients' hesitation to enroll in cancer trials. Despite trusting their medical teams, some patients express concerns about the purpose of research and its potential impact on their health and community.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A new study found that hypofractionation does not increase complications for patients with breast cancer who undergo mastectomy and plan breast reconstruction. The trial enrolled 898 patients and showed that reducing treatment time by nearly half is safe and effective, saving patients time and money.
A study published in Blood Advances found that CAR-T therapy can be administered safely and effectively on an outpatient basis in community hospitals, mitigating barriers to access. The treatment showed high efficacy rates, with 80% of patients experiencing an objective response and 54% achieving a complete response.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Early-stage HR+ breast cancer survivors experience weight gain, particularly those with healthy BMI or overweight at diagnosis. Black women have higher rates of obesity and related comorbidities compared to White women, leading to a 40% higher breast cancer mortality rate.
A recent study reveals that pharmaceutical industry sponsors dominate US cancer research, with a substantial increase in industry-sponsored clinical trials over the past decade. Federally funded studies have been underinvested and have missed opportunities for scientific advancements.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
A new online tool has been shown to reduce decisional conflict in women with breast cancer undergoing mastectomy, supporting informed decisions on immediate breast reconstruction. The study found that patients who used the tool felt better prepared for decision-making and had a lower rate of clinically significant decisional conflict.
Researchers have developed a new method to detect melanoma using tumour-specific antibodies, which can accurately identify stage I and II melanoma patients. The study found that these antibodies showed high sensitivity and specificity in detecting melanoma, with an AUC value of up to 0.981.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
Dr. Roger Lo has been awarded a $2 million NIH grant to investigate ways to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors. The team aims to target genetic instability and immune evasion to stabilize the melanoma genome and make it more vulnerable to immune attacks.
A new risk prediction model identifies patients with advanced cancer who are at highest risk for unplanned emergency room visits and hospital stays. The model, developed by researchers from the SWOG Cancer Research Network, considers factors such as performance status, comorbidities, and cancer type.
The Affordable Care Act has led to increased guideline-concordant care for non-white patients, rural residents, and those from the most deprived neighborhoods in Pennsylvania. This improvement is associated with better cancer outcomes, including survival rates.
A study found that Black women with breast cancer are more likely to experience vaginal dryness, reduced libido, and painful intercourse, leading to lower mental quality of life. These symptoms were associated with decreased adherence to treatment in these patients.
A nonrandomized clinical trial found that wearable devices can increase moderate-to-vigorous physical activity and reduce dyspnea at 6 months post-lung cancer surgery. This suggests a promising role for wearable devices in personalizing perioperative rehabilitation strategies.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center developed a biobank of 294 samples from 126 patients with 25 different subtypes of bone and soft tissue sarcoma. The team created tumor organoids that retained key characteristics of the original tumors, which were then subjected to high-throughput drug screening. They iden...
A new study found that vulnerable patients treated at Commission on Cancer-accredited hospitals had a 9% lower mortality rate and were more likely to receive guideline-based care. This is attributed to CoC accreditation requirements for treatment guideline adherence, community engagement, and addressing barriers to care.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
Researchers discovered ponsegromab, a monoclonal antibody, improves symptoms of cachexia by blocking the GDF-15 hormone. The treatment shows minimal side effects and boosts weight gain and patient activity in cancer patients.
A recent study found a correlation between higher anti-PD-1 autoantibody levels and lower survival rates in patients with advanced liver cancer, suggesting these autoantibodies as potential biomarkers for predicting treatment response. The discovery aims to improve treatment regimens for patients with liver cancer.
Researchers have developed a novel platform for testing radiation therapy effects on brain cells, providing insights into how the brain reacts to cancer treatment. The study aims to improve treatment strategies by understanding the impact of radiation on neural circuits, ultimately leading to personalized care for patients.
A clinical trial found that an oral cancer drug reduced nosebleed severity and improved quality of life in patients with hereditary hemorrhagic telangiectasia (HHT). The PATH-HHT study showed significant improvements in disease manifestations, including severe nosebleeds and chronic gastrointestinal bleeding.
A Northwestern University study finds that cancer patients prefer their providers assess their financial concerns early in treatment. Most patients (83%) want their providers to reach out regarding financial needs, with 82% preferring this at diagnosis or starting treatment.
A meta-analysis by Mass General Brigham researchers found that Black women face higher mortality rates from breast cancer across all tumor subtypes, attributed to socioeconomic inequality, delayed diagnosis, and inadequate access to timely quality treatment. This disparity is not limited to hormone-positive tumors, with differences als...
The CABINET trial demonstrates that cabozantinib significantly improves median progression-free survival (PFS) for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The treatment also shows promise across all clinical subgroups, including primary tumor site and grade.
Patients with low-risk cancers undergoing active surveillance experience anxiety caused by uncertainty, a problem that persists even after diagnosis, leading to negative responses such as fear and avoidance of decision-making. Medical interventions are needed to address this anxiety and improve patient-centered care.
A new clinical trial shows that immunotherapy treatment with pembrolizumab can significantly extend the cancer-free period for patients with high-risk, muscle-invasive bladder cancer. The study found that adjuvant pembrolizumab treatment nearly doubled the median length of time patients remained cancer-free compared to observation.
A double-blind randomized phase 3 clinical trial found no additional benefits from high-dose vitamin D3 when added to standard chemotherapy for patients with untreated metastatic colorectal cancer. However, a potential benefit was observed for left-sided disease patients.
Two studies found breastfeeding after breast cancer diagnosis is safe and feasible for young patients with specific genetic variations, as well as hormone receptor-positive breast cancer survivors. A third study shows a telephone-based coaching program can significantly increase physical activity in overweight patients, potentially imp...
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
A drug that delivers chemotherapy directly to tumors has shown substantial and durable activity in treating brain metastases of HER2-positive breast cancer. The treatment, trastuzumab deruxtecan, has improved progression-free survival and objective response rates in patients with advanced disease.
A study published in JAMA Network Open found that body mass index (BMI) has a more complex relationship with mortality risk during cancer therapy than previously thought. For patients with advanced non-small cell lung cancer, higher BMI was associated with lower mortality when undergoing immunotherapy or conventional chemotherapy. Howe...
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
A study by IRB Barcelona researchers has identified five independent factors that determine patients' response and survival after receiving checkpoint inhibitors, a type of immunotherapy. These findings provide a framework for current and future biomarkers of immunotherapy response and could lead to more accurate patient classification.
A groundbreaking study has provided novel insights into the molecular underpinnings of gastric cancer peritoneal spread, paving the way for more effective treatments. The research also demonstrated the safety and potential efficacy of a new treatment approach in a clinical trial.
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
A recent study published in JAMA found that telehealth delivery of early palliative care is equivalent to in-person care in terms of quality of life outcomes for patients with advanced non-small cell lung cancer. This finding highlights the potential benefits of expanding access to this evidence-based care model through telehealth.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
New vaccines are being explored as a promising approach to treating glioblastoma, a highly lethal brain cancer with limited treatment options. These vaccines have been generally well-tolerated and have shown promise in improving survival rates for GBM patients.
Research found that first-degree relatives and spouses of cancer patients are at higher risk of developing psychological and cardiovascular illnesses. The study used data from the Utah Population Database to compare 77,938 relatives and spouses with 81,022 controls, finding a 10% increase in psychological condition risks and a 28% incr...
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
A groundbreaking study published in Nature Medicine reports the first sustained remission of HIV infection following a bone marrow transplant in a patient without the CCR5-delta 32 mutation. Despite remaining susceptible to HIV, the virus remains undetectable nearly three years after antiretroviral treatment was stopped.
A University of Leicester study has found that certain gut bacteria may influence whether a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer. Researchers suggest that dietary changes, such as increased fibre intake, could improve the benefits of immunotherapy for these patients.
A team at NUS Yong Loo Lin School of Medicine leveraged an artificial intelligence-derived platform, CURATE.AI, to guide treatment for a patient with Waldenström macroglobulinemia, a rare blood disorder. The trial demonstrated substantial improvement in red blood cell levels and minimised side effects.
A Mass General Brigham-led study found that a large language model improves the accuracy of immune-related adverse event detection, identifying additional cases not picked up by manual adjudication. The model demonstrated excellent specificity and sensitivity, opening up opportunities for collaboration among institutions.
A recent study reveals racial disparities in cancer stage at diagnosis and survival for adolescents and young adults, highlighting the need for tailored interventions to achieve cancer care equity. The findings support health policy and funding implications, emphasizing the importance of addressing these disparities.
Researchers explore AI's role in addressing challenges in immunotherapy, developing new biomarkers for precise disease characterization and predicting treatment response. A comprehensive review applied AI/radiomics to cross-sectional imaging, showcasing the current landscape in IO treatment.
Women with regular annual mammograms had higher overall survival and lower late-stage cancer rates than those screened less frequently. The study's findings contradict current guidelines, suggesting a significant benefit to annual screening for women over 40.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.
A systematic review and meta-analysis found that cognitive behavioral therapy (CBT) moderately improves mental health and quality of life in people with past or current cancer. CBT was more effective for younger individuals and in-person delivery compared to technology-based platforms.
A pivotal study supports belzutifan approval for patients with advanced kidney cancer, with belzutifan demonstrating a 25% lower risk of progression compared to everolimus. The HIF-2 inhibitor offers a novel therapeutic mechanism in advanced renal cell carcinoma treatment.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.